Localized Affinity-Based Delivery of Prinomastat for Cancer Treatment

Area of Science:

• Oncology
• Biomaterials Science
• Drug Delivery

Background:

• Glioblastoma multiforme (GBM) has a poor prognosis, with a median survival of 14 months.
• GBM's invasive nature contributes to its resistance to conventional therapies.
• Matrix metalloproteinases (MMPs) are crucial for cancer cell invasion and extracellular matrix degradation.

Purpose of the Study:

• To investigate the efficacy of localized prinomastat delivery using cyclodextrin polymers for glioblastoma treatment.
• To assess the potential of this delivery system to mitigate systemic side effects associated with prinomastat.
• To evaluate the duration of MMP inhibition achieved by prinomastat-loaded cyclodextrin polymers.

Main Methods:

• Prinomastat was encapsulated within beta-cyclodextrin polymers.
• The inhibition of MMPs was measured using gelatin zymography.
• The duration of MMP inhibition was assessed over several months.

Main Results:

• Prinomastat delivery from beta-cyclodextrin polymers resulted in sustained inhibition of MMPs.
• The observed inhibition lasted for months, aligning with the timeline of cancer cell invasion.
• This localized delivery approach bypasses the systemic side effects of conventional prinomastat administration.

Conclusions:

• Localized delivery of prinomastat via cyclodextrin polymers offers a promising strategy for managing glioblastoma multiforme.
• This method effectively inhibits MMPs, crucial for cancer invasion, while minimizing adverse effects.
• The prolonged inhibition achieved by this formulation addresses the temporal needs of combating cancer cell invasion.